Currently, the number of percutaneous coronary interventions (PCI) performed in acute and chronic forms of coronary heart disease continues to grow: every year their number reaches at least 5,000,000 worldwide, and more than 200,000 of them in Russia. The main causes of postoperative mortality are perioperative myocardial infarction and acute heart failure due to inadequate protection of the myocardium from ischemia/reperfusion under conditions of balloon expansion and stenting of the affected coronary arteries. The review presents experimental and clinical literature data on the successful use of levocarnitine for cardioprotection in patients with various forms of coronary heart disease and patients with chronic heart failure, both with intravenous administration and as part of a cardioplegic solution during heart surgery. The intracoronary route of administration of levocarnitine solution during PCI in high-risk patients (elderly and senile patients, with multivessel lesions of the coronary bed, difficulties in conducting the intervention) is substantiated. The description of two clinical cases of the use of the technique in elderly patients with acute forms of coronary heart disease with multivessel lesion is given. The postoperative period proceeded without complications with smooth dynamics of biomarkers (troponin I, total creatinephosphokinase, MB-fraction of creatinephosphokinase, lactate dehydrogenase), ischemic ECG shifts were little pronounced. The expected results of the application of the technique are a reduction in intraoperative and postoperative complications of ischemia/ reperfusion and an increase in the effectiveness of the clinical results of PCI in high-risk patients.
This review aims to provide information on myocarditis and inflammatory cardiomyopathies associated with immune checkpoint inhibitor (ICI) therapies. Additionally, it will present current data on strategies for diagnosis and treatment of these conditions. As immunotherapy becomes more widely used, it has revealed diverse clinical symptoms, courses, and outcomes of cardiovascular immune-related adverse events (irAEs). These range from rare but potentially life-threatening fulminant forms to mild symptomatic courses that can lead to the development of dilated cardiomyopathy, arrhythmias, and heart failure. The review discusses the risk factors and common comorbid clinical conditions of irAE-associated myocarditis, as well as severity assessment and observation algorithms. The importance of a multidisciplinary approach to managing patients with this cardiotoxic irAE is also emphasized. В обзоре представлены сведения о миокардитах и воспалительных кардиопатиях, связанных с терапией ингибиторами иммунных контрольных точек (ИКТ), имеющиеся современные данные о стратегиях их диагностики и лечения. Широкое практическое применение иммунотерапии постепенно стало выявлять разнообразную клиническую симптоматику, течение и исходы иммуноопосредованных кардиологических нежелательных явлений (иНЯ) от достаточно редких, но потенциально жизнеопасных фульминантных форм, до малосимптомных вариантов течения, которые, однако, нередко приводят к развитию дилатационной кардиопатии, аритмий и сердечной недостаточности. Рассматриваются факторы риска, частые сопутствующие клинические состояния иммуноопосредованных миокардитов, вопросы оценки степени тяжести иНЯ, алгоритмы наблюдения. Подчеркивается важность мультидисциплинарного подхода к решению проблем ведения пациентов при развитии этого кардиотоксического иНЯ.
1 December 2019 in HERALD of North-Western State Medical University named after I.I. Mechnikov
Purpose. Presentation of clinical signs and laboratory profiles of the patients with chronic fatigue syndrome, and comparison of their symptoms with those of the patients with iron deficiency anemia. Materials and methods. Retrospective analysis of the patients symptoms referred to the hematologist outpatient clinic during the period between January 2016 and December 2018. Results. There were 560 patients(162 males and 398 females) referred for a primary consultation by a hematologist. Median age was 52.5 (1894) years. The unexplained fatigue was reported by 27 (4.8%) patients (1 male and 26 females), median age 41 (2466) years. Diagnosis chronic fatigue syndrome (CFS) was confirmed based on the criteria in 17 (63%) patients. 10 patients (47%) with symptoms partially meeting the criteria were diagnosed idiopathic fatigue syndrome (SIF). Half of the patients connected the onset of the diseases with emotional trauma (family issues etc.). The prevailing complaints (30%) were represented by: prolonged fatigue, mild memory impairment and distraction, arthralgia and insomnia. The most frequent reason to see a hematologist was fatigue and borderline changes in the blood tests. Five patients with CFS and 2 patients with SIF were known to have previously diagnosed iron deficient anemia (IDA). Median level of hemoglobin in the patients with severe fatigue and IDA was 10.7 (8.411.7) g/dl. Median follow up duration was 28 (640) months. In the observed group (n = 23) 17% of the patients (n = 4) showed spontaneous improvement. The rest of the patients had reported no changes. The comparison group (n = 64) included the patients with IDA. Most of them (n = 38) did not report fatigue as their initial symptoms (median level of hemoglobin was 9.35 (5.511.9) g/dl). Twenty six patients reported fatigue; median level of hemoglobin was 8.15 (5.911.7) g/dl. The difference between the hemoglobin levels in two groups was significant (р 0.05). However, there was no correlation between the level of hemoglobin and fatigue in the patients with CFS and SIF. The correlation was found in the patients with CFS and SIF between fatigue and patients perception. Conclusion. The main symptoms accompanying CFS are fatigue and other non-specific symptoms which are often related to patients emotional status. Considering CFS as a differential diagnosis when dealing with fatigue is essential.
BACKGROUND: Immune checkpoint inhibitors are highly effective in treating malignant neoplasms, but they often cause immune-related adverse events. The mechanisms of their pathogenesis are not well understood, and there are no reliable markers in clinical practice for assessing the risk of their occurrence. This study addresses the lack of research by validating a panel of markers. This will allow for personalized preventive management of patients and reduce the frequency of premature treatment discontinuation. AIM: The study aimed to identify the most informative prognostic markers for immune-related adverse events by evaluating dynamic changes in plasma cytokine levels in patients with malignant neoplasms who were receiving checkpoint inhibitor therapy. METHODS: A prospective study of patients with malignant neoplasms receiving checkpoint inhibitor therapy was conducted between 2023 and 2024 at the St. Petersburg Hospital of the Russian Academy of Sciences. The risk of immune-related adverse events was assessed as part of the dynamic observation (105 days with 2.0–2.5-week intervals). The primary endpoint was changes in plasma cytokine concentrations, determined by multiplex analysis and analyzed using nonparametric statistical tests such as the Shapiro–Wilk test, Mann–Whitney U test, and Šidák correction. RESULTS: The study included 21 patients with malignant neoplasms who completed the entire observation program. Six patients (28.6%) developed immune-related adverse events, whereas 15 (71.4%) did not. The development of immune-related adverse events was found to be associated with a significant increase in cytokine concentrations, suggesting a predominance of type 1 and type 17 T-helper cells. Of the evaluated biomarkers, interleukin 12p70 (IL-12p70), IL-15, and transforming growth factor-beta (TGF-β) had the greatest prognostic value for predicting complications. These biomarkers exhibited high sensitivity and specificity in pairwise group comparisons (p 0.005). During the manifestation of immune-related adverse events, the plasma concentrations of the following markers were as follows: IL 12p70: 2.51 [2.09–2.93] pg/mL; TGF-β: 14.54 [13.52–17.12] ng/mL; IL-15: 20.86 [15.51–26.21] pg/mL. The analysis confirmed that these markers are the most reliable predictors of an excessive immune response. No complications unrelated to the primary mechanism of action of the study therapy were reported. CONCLUSION: This study demonstrated for the first time the possibility of a predictive risk assessment for immune-related adverse events prior to checkpoint inhibitor therapy initiation based on IL-12p70, IL-15, and TGF-β levels. These findings allow for personalized patient management strategies that balance treatment efficacy with the prevention of complications. The study had two main limitations: its small sample size (n = 21) and the fact that patients were recruited from a single site.
22 February 2026 in Cardiovascular Therapy and Prevention